Marganit Farago, Ph.D.
Affiliations: | 2007 | Boston University, Boston, MA, United States |
Area:
Cell Biology, Molecular Biology, OncologyGoogle:
"Marganit Farago"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| David C. Seldin | grad student | 2007 | Boston University | |
| (Roles of the serine -threonine kinases glycogen synthase kinase -3 beta and protein kinase CK2 in mammary tumorigenesis and epithelial to mesenchymal transition.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Shalom B, Farago M, Salaymeh Y, et al. (2022) Vav1 Promotes B-Cell Lymphoma Development. Cells. 11 |
| Shalom B, Farago M, Pikarsky E, et al. (2018) Vav1 mutations identified in human cancers give rise to different oncogenic phenotypes. Oncogenesis. 7: 80 |
| Sebban S, Farago M, Rabinovich S, et al. (2014) Vav1 promotes lung cancer growth by instigating tumor-microenvironment cross-talk via growth factor secretion. Oncotarget. 5: 9214-26 |
| Lazer G, Pe'er L, Farago M, et al. (2010) Tyrosine residues at the carboxyl terminus of Vav1 play an important role in regulation of its biological activity. The Journal of Biological Chemistry. 285: 23075-85 |
| Schlezinger JJ, Liu D, Farago M, et al. (2006) A role for the aryl hydrocarbon receptor in mammary gland tumorigenesis. Biological Chemistry. 387: 1175-87 |
| Seldin DC, Landesman-Bollag E, Farago M, et al. (2005) CK2 as a positive regulator of Wnt signalling and tumourigenesis. Molecular and Cellular Biochemistry. 274: 63-7 |
| Currier N, Solomon SE, Demicco EG, et al. (2005) Oncogenic signaling pathways activated in DMBA-induced mouse mammary tumors. Toxicologic Pathology. 33: 726-37 |
| Farago M, Dominguez I, Landesman-Bollag E, et al. (2005) Kinase-inactive glycogen synthase kinase 3beta promotes Wnt signaling and mammary tumorigenesis. Cancer Research. 65: 5792-801 |